Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Rhea-AI Summary
Pelthos Therapeutics (NYSE American: PTHS) will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. A conference call and Q&A will be held at 8:00 a.m. Eastern Time the same day.
Investors can join via toll-free dial-in, international number, conference ID 13758894, or a live webcast at the provided URL.
Positive
- None.
Negative
- None.
News Market Reaction – PTHS
In the Mar 9 session, PTHS declined 0.30%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Conference appearance | Positive | +5.0% | CEO presentation at Oppenheimer healthcare conference with webcast and meetings. |
| Jan 13 | Debt financing | Positive | -1.3% | Up to $50M senior secured term loan facility to support product launches. |
| Jan 05 | Product acquisition | Positive | -9.0% | Acquisition of FDA-approved Xeglyze head-lice treatment for $1.8M. |
| Dec 23 | Board appointment | Neutral | -1.8% | Appointment of experienced finance executive Andrew Einhorn to board roles. |
| Dec 04 | Access agreement | Positive | +0.6% | PBM agreement expanding ZELSUVMI access to over 20M covered lives. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive commercial and financing news has produced mixed share reactions, with some strategic wins sold off and some events bid up.
Over the last few months, Pelthos has focused on commercialization and balance sheet actions. A PBM deal expanding ZELSUVMI access on Dec 4, 2025 saw only a modest 0.61% move. The Xeglyze acquisition on Jan 5, 2026 coincided with a -9.03% reaction. The Horizon term loan on Jan 13, 2026 led to a slight -1.31% move, while an Oppenheimer conference appearance on Feb 23, 2026 aligned with a 5.04% gain. Today’s earnings-date notice fits into this ongoing commercial build-out and financing story.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to hold a conference call at 8:00 a.m. ET
DURHAM, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. The company will hold a conference call followed by a question-and-answer period at 8:00 a.m. Eastern Time.
Details for the conference call can be found below:
| Date: | Thursday, March 19, 2026 |
| Time: | 8:00 a.m. Eastern Time |
| Toll Free: | 1-877-451-6152 |
| International: | 1-201-389-0879 |
| Conf.ID: | 13758894 |
| Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1753536&tp_key=4e91699655 | |
About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI™ (berdazimer) topical gel,
Contacts
Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com
Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072
